Insmed Beats Q3 Revenue Estimates and Lifts Full-Year Guidance Range
INSM sits 22% above its 52-week low of $90.39 on elevated volume (2.5× avg).
Summary
Insmed beat Q3 revenue expectations and raised its full-year revenue guidance range, and the stock is surging on the news. The quarter itself was already on the tape this morning: total revenue of $524.4 million, up 268% from $142.3 million a year ago, with $398.1 million of US BRINSUPRI sales and the net loss narrowing to $100.3 million. The guidance raise is the incremental piece — it extends the pattern from Q2, when the company also lifted BRINSUPRI guidance after a $425.5 million quarter that came in well above the $392.84 million consensus. Momentum behind the bronchiectasis launch is the whole story here, and management is now telling the market the second half runs ahead of prior expectations. Note the CFO transition: Sara Bonstein steps down October 30, so the next quarterly update lands under new finance leadership.
At the time of this announcement, INSM was trading at $110.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.2B. The 52-week trading range was $90.39 to $212.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.